<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579380</url>
  </required_header>
  <id_info>
    <org_study_id>SGNTUC-019</org_study_id>
    <nct_id>NCT04579380</nct_id>
  </id_info>
  <brief_title>Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations</brief_title>
  <official_title>A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well tucatinib works for solid tumors that make either more HER2 or a&#xD;
      different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial&#xD;
      have either spread to other parts of the body (metastatic) or cannot be removed completely&#xD;
      with surgery (unresectable).&#xD;
&#xD;
      All participants will get both tucatinib and trastuzumab. People with hormone-receptor&#xD;
      positive breast cancer will also get a drug called fulvestrant.&#xD;
&#xD;
      The trial will also look at what side effects happen. A side effect is anything a drug does&#xD;
      besides treating cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are multiple cohorts in this trial:&#xD;
&#xD;
        -  5 tumor specific cohorts with HER2 overexpression/amplification (cervical cancer,&#xD;
           uterine cancer, biliary tract cancer, urothelial cancer, and non-squamous non-small cell&#xD;
           lung cancer [NSCLC])&#xD;
&#xD;
        -  2 tumor specific cohorts with HER2 mutations (non-squamous NSCLC and breast cancer)&#xD;
&#xD;
        -  2 cohorts which will enroll all other HER2 amplified/overexpressed solid tumor types&#xD;
           (except breast cancer, gastric or gastroesophageal junction adenocarcinoma [GEC], and&#xD;
           colorectal cancer [CRC]) or HER2-mutated solid tumor types.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed objective response rate (cORR) per investigator assessment</measure>
    <time_frame>From start of treatment up to approximately 2 years</time_frame>
    <description>cORR is defined as the proportion of participants with best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) per investigator assessment</measure>
    <time_frame>From start of treatment up to approximately 2 years</time_frame>
    <description>DCR is defined as the proportion of participants with confirmed CR, confirmed PR, or stable disease according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per investigator assessment</measure>
    <time_frame>From start of treatment up to approximately 2 years</time_frame>
    <description>DOR is defined as the time from first documentation of objective response of confirmed CR or confirmed PR to the first documentation of disease progression per RECIST v1.1 or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) per investigator assessment</measure>
    <time_frame>From start of treatment up to approximately 2 years</time_frame>
    <description>PFS is defined as the time from the date of treatment initiation to the date of disease progression according to RECIST v1.1 or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From start of treatment up to approximately 4 years</time_frame>
    <description>OS is defined as the time from treatment initiation to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>From start of treatment up to approximately 2 years</time_frame>
    <description>Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>From start of treatment up to approximately 2 years</time_frame>
    <description>To be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose alterations</measure>
    <time_frame>From start of treatment up to approximately 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Approximately 4 months, during first 6 cycles of treatment</time_frame>
    <description>To be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough concentration (Ctrough)</measure>
    <time_frame>Approximately 4 months, during first 6 cycles of treatment</time_frame>
    <description>To be summarized using descriptive statistics.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Uterine Neoplasms</condition>
  <condition>Uterine Cervical Neoplasms</condition>
  <condition>Biliary Tract Neoplasms</condition>
  <condition>Urologic Neoplasms</condition>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Tucatinib + Trastuzumab (+ Fulvestrant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tucatinib</intervention_name>
    <description>300 mg orally twice daily</description>
    <arm_group_label>Tucatinib + Trastuzumab (+ Fulvestrant)</arm_group_label>
    <other_name>TUKYSA, ARRY-380, ONT-380</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <description>Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1</description>
    <arm_group_label>Tucatinib + Trastuzumab (+ Fulvestrant)</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.</description>
    <arm_group_label>Tucatinib + Trastuzumab (+ Fulvestrant)</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of locally-advanced unresectable&#xD;
             or metastatic solid tumor, including primary brain tumors&#xD;
&#xD;
          -  Participants with non-squamous NSCLC must have progressed during or after standard&#xD;
             treatment or for which no standard treatment is available&#xD;
&#xD;
          -  Participants with other disease types must have progressed during or after â‰¥1 prior&#xD;
             line of systemic therapy for locally-advanced unresectable or metastatic disease&#xD;
&#xD;
          -  Disease progression during or after, or intolerance of, the most recent line of&#xD;
             systemic therapy&#xD;
&#xD;
          -  Disease demonstrating HER2 alterations (overexpression/amplification or HER2&#xD;
             activating mutations), as determined by local or central testing processed in a&#xD;
             Clinical Laboratory Improvement Amendments (CLIA)- or International Organization for&#xD;
             Standardization (ISO) accredited laboratory, according to one of the following:&#xD;
&#xD;
               -  HER2 overexpression/amplification from fresh or archival tumor tissue or blood&#xD;
&#xD;
               -  Known activating HER2 mutations detected in fresh or archival tumor tissue or&#xD;
                  blood&#xD;
&#xD;
          -  Have measurable disease per RECIST v1.1 criteria according to investigator assessment&#xD;
&#xD;
          -  Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Participants with breast cancer, gastric or gastroesophageal junction adenocarcinoma,&#xD;
             or CRC whose disease shows HER2 amplification/overexpression.&#xD;
&#xD;
          -  Previous treatment with HER2-directed therapy; participants with uterine serous&#xD;
             carcinoma or HER2-mutated gastric or gastroesophageal junction adenocarcinoma without&#xD;
             HER2-overexpression/amplification may have received prior trastuzumab&#xD;
&#xD;
          -  Known hypersensitivity to any component of the drug formulation of tucatinib or&#xD;
             trastuzumab (drug substance, excipients, murine proteins), or any component of the&#xD;
             drug formulation of fulvestrant in participants with HR+ HER2-mutated breast cancer&#xD;
&#xD;
          -  History of exposure to a 360 mg/mÂ² doxorubicin-equivalent or &gt;720 mg/m^2&#xD;
             epirubicin-equivalent cumulative dose of anthracyclines&#xD;
&#xD;
          -  Treatment with any systemic anti-cancer therapy, radiation therapy, major surgery, or&#xD;
             experimental agent within â‰¤3 weeks of first dose of study treatment or are currently&#xD;
             participating in another interventional clinical trial.&#xD;
&#xD;
        There are additional inclusion and exclusion criteria. The study center will determine if&#xD;
        criteria for participation are met.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Ramos, DO</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>8663337436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HAL</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Flores</last_name>
      <phone>480-860-2540</phone>
    </contact>
    <investigator>
      <last_name>Bradley Monk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Gano</last_name>
      <phone>480-301-4961</phone>
    </contact>
    <investigator>
      <last_name>Tanios Bekaii-Saab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center / University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Rippe</last_name>
      <phone>520-694-9049</phone>
    </contact>
    <investigator>
      <last_name>Rachna Shroff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego / Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Padilla</last_name>
      <phone>858-822-6276</phone>
    </contact>
    <investigator>
      <last_name>Rana R McKay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Phan</last_name>
      <phone>562-590-0345</phone>
    </contact>
    <investigator>
      <last_name>Danny Nguyen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jenny Fox</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates</name>
      <address>
        <city>Manchester</city>
        <state>Connecticut</state>
        <zip>06040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary-Beth Moran</last_name>
      <phone>860-646-0670</phone>
    </contact>
    <investigator>
      <last_name>Joseph McLaughlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lombardi Cancer Center / Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Salsini</last_name>
      <phone>202-687-9016</phone>
    </contact>
    <investigator>
      <last_name>Paula Pohlmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcus S Noel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kabir Mody</last_name>
    </contact>
    <investigator>
      <last_name>Kabir Mody</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adel Yazdankhahkenary</last_name>
      <phone>813-745-0164</phone>
    </contact>
    <investigator>
      <last_name>Solmaz Sahebjam</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hatem H Soliman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teju Chakravarthy</last_name>
    </contact>
    <investigator>
      <last_name>Dejan Juric</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Mahipal</last_name>
      <phone>507-284-0923</phone>
    </contact>
    <investigator>
      <last_name>Amit Mahipal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HealthPartners Institute</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kelly</last_name>
      <phone>952-993-0996</phone>
    </contact>
    <investigator>
      <last_name>Daniel M Anderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kacie Gebhardt</last_name>
      <phone>314-747-3678</phone>
    </contact>
    <investigator>
      <last_name>Premal Thaker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Cordes</last_name>
      <phone>402-691-6970</phone>
    </contact>
    <investigator>
      <last_name>Muhammad S Haroon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Himmel</last_name>
      <phone>516-663-1216</phone>
    </contact>
    <investigator>
      <last_name>Bhavana Pothuri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Penina Stewart</last_name>
    </contact>
    <investigator>
      <last_name>Matthew Galsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Shoemaker</last_name>
      <email>debra.shoemaker@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Stinchcombe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University / University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shyanne Pierce</last_name>
      <phone>216-844-5018</phone>
    </contact>
    <investigator>
      <last_name>Afshin Dowlati</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Deb Bruno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)/Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Berger</last_name>
      <phone>412-641-6373</phone>
    </contact>
    <investigator>
      <last_name>Alexander Olawaiye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Larson</last_name>
      <phone>864-987-7000</phone>
    </contact>
    <investigator>
      <last_name>Ki Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology-Nashville/Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Kennedy</last_name>
      <phone>615-329-7255</phone>
    </contact>
    <investigator>
      <last_name>Erika P Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - West Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Garcia</last_name>
      <phone>325-692-0188</phone>
    </contact>
    <investigator>
      <last_name>Anton Melnyk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A. - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Barrera</last_name>
      <phone>214-370-1914</phone>
    </contact>
    <investigator>
      <last_name>Joyce O'Shaughnessy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>US Oncology Central Regulatory</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bradley Monk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Waco</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Fonseca</last_name>
    </contact>
    <investigator>
      <last_name>Carl G Chakmakjian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arun Athithan</last_name>
      <phone>801-587-4624</phone>
    </contact>
    <investigator>
      <last_name>Sumati Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Becker</last_name>
      <phone>703-894-3800</phone>
    </contact>
    <investigator>
      <last_name>Alexander I Spira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Amador</last_name>
      <phone>206-606-6630</phone>
    </contact>
    <investigator>
      <last_name>Evan Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Bigler</last_name>
    </contact>
    <investigator>
      <last_name>David Cosgrove</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carbone Cancer Center / University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Warnell</last_name>
      <phone>608-890-1614</phone>
    </contact>
    <investigator>
      <last_name>Elisavet Paplomata</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Burkard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <state>Other</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cedric Van Marcke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grand Hopital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <state>Other</state>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Luc Canon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <state>Other</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans Prenen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Liege</name>
      <address>
        <city>Liege</city>
        <state>Other</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guy Jerusalem</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Chiba</city>
        <state>Other</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yoshiaki Nakamura</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Other</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Satoru Iwasa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Marianna University School of Medicine</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Other</state>
        <zip>2168511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yu Sunakawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Other</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nobumasa Mizuno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osakasayama</city>
        <state>Other</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hidetoshi Hayashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Tokyo</city>
        <state>Other</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shunji Takahashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Seung Tae Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Do-Youn Oh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <state>Other</state>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sang Joon Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <state>Other</state>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hendrik-Tobias Arkenau</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <keyword>Uterine cancer</keyword>
  <keyword>Biliary tract cancer</keyword>
  <keyword>Urothelial cancer</keyword>
  <keyword>Non-squamous non-small cell lung cancer</keyword>
  <keyword>Non-squamous NSCLC</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>Ampullary cancer</keyword>
  <keyword>Solid tumors</keyword>
  <keyword>Solid tumors harboring somatic HER2 mutations</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Urologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Tucatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

